08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
U.S. employers and foreign workers could soon face significant additional burdens and years-long del...
Read More >
The DE OFCCP Week in Review (WIR) is a simple, fast and direct summary of relevant happenings in the...
Read More >
As healthcare providers around the country struggle to respond to patient needs during the Covid-19 ...
Read More >
The European Commission on March 25 issued guidelines addressed to its member states outlining an EU...
Read More >
In many states, the implied warranties of workmanship and habitability automatically attach to contr...
Read More >
The task of securing company networks and systems is no longer delegated solely to an organization’...
Read More >